As the world contends with the ripple effects caused by the coronavirus outbreak, ZS experts are developing strategies and insights to help you navigate these uncertain times and plan for what’s next.

Pharma's new mission: Bridging the care gap

Pharma's new mission: Bridging the care gap


"This global crisis could become the pharmaceutical industry’s finest hour," write three ZS pharma experts. "To make good on this promise, the industry will make contributions beyond developing treatments and vaccines that put this disease behind us."
READ THE ARTICLE

 

Insights

+ Evolving healthcare landscape

A message for medtechs: Adapt for the future while you can

A message for medtechs: Adapt for the future while you can


ZS's Brian Chapman spoke with In Vivo about recognizing medtech's value and why "things must never go back to where they were."
READ THE ARTICLE IN IN VIVO INFORMA PHARMA INTELLIGENCE

Current and past trends in life sciences deal-making activity

Current and past trends in life sciences deal-making activity


ZS experts are monitoring life sciences deal-making and funding activity to investigate the broader impact of COVID-19 on M&A. Here’s what they found.
READ THE ARTICLE

Biopharma’s Response: Near-Term Next Steps

Biopharma’s Response: Near-Term Next Steps


ZS held a roundtable discussion with several key clients to discuss what the future of biopharma will look like post-COVID-19. Here’s what they had to say.
READ THE SUMMARY

How can health plans prepare for the ‘new normal’ when ‘normal’ keeps changing?

How can health plans prepare for the ‘new normal’ when ‘normal’ keeps changing?


New ZS research shows the impact that COVID-19 will have on health plan enrollment over the next 18 months.
READ THE ARTICLE

Payers and Providers should re-evaluate their digital strategy to prepare for the future

Payers and Providers should re-evaluate their digital strategy to prepare for the future


With solutions like telehealth becoming mainstream overnight, payers and providers must rethink their digital strategies. As you review yours, focus on these five strategic imperatives.
READ THE ARTICLE

Survey: US payers feel well-positioned to survive COVID-19

Survey: US payers feel well-positioned to survive COVID-19


New ZS research shows that U.S. payers expect a delay in product approvals of only two to four months—a much shorter duration than what payers in other countries are expecting. ZS’s Ed Schoonveld weighs in on the full findings.
READ THE ARTICLE IN FIERCEHEALTHCARE

New ZS Research: Adapting to COVID-19

New ZS Research: Adapting to COVID-19


ZS research with patients and providers indicates a significant disruption to the continuity of care, and points to the growing importance of alternate models of care.
ACCESS OUR FINDINGS

New ZS Research: Emerging From COVID-19

New ZS Research: Emerging From COVID-19


As the impact of COVID-19 intensifies, customer-led engagement will become the new normal, according to new ZS research. Take a look at the full findings and ZS’s insights on what pharma companies should do to evolve.
ACCESS OUR FINDINGS

Why now is the time to adjust your pricing and contracting strategy

Why now is the time to adjust your pricing and contracting strategy


Leaders need to create new short-, medium- and long-term pricing and contracting strategies to mitigate revenue leakage and maintain average selling price and market share to create processes for long-term success. Here’s how.
READ THE ARTICLE

How Medicare Advantage stars teams should navigate COVID-19

How Medicare Advantage stars teams should navigate COVID-19


Medicare Advantage plans have a great opportunity to support their members and adapt their longer-term performance strategy in light of changes in the healthcare landscape. Here’s how they can plan for the future and stay ahead of the curve.
READ THE ARTICLE

Health plans’ role in value-based care just got more complicated

Health plans’ role in value-based care just got more complicated


Looking ahead to a post-pandemic world, health plans can take a three-pronged approach to build long-term trust with providers and create more durable uptake of value-based care programs.
READ THE ARTICLE

The COVID-19 Payer Pulse survey

The COVID-19 Payer Pulse survey


85% of payers wish to collaborate with pharma on vaccine programs, according to new ZS research. Read on for more exclusive insights.
READ THE ARTICLE

How COVID-19 will remake healthcare in the Western world

How COVID-19 will remake healthcare in the Western world


ZS’s Brian Chapman shares five trends—from the rise of in-home testing to rethinking the hospital supply chain—that medtech companies should anticipate.
READ THE ARTICLE

ZS's COVID-19 Payer Pulse Survey

ZS's COVID-19 Payer Pulse Survey


ZS conducted the COVID-19 Payer Pulse survey to provide insight into payer perspectives on the impact and implications of the pandemic. View the key findings.
VIEW THE INFOGRAPHIC

Will COVID-19 make providers more risk averse?

Will COVID-19 make providers more risk averse?


Although provider organizations could become more risk averse because of COVID-19, health plans can limit the damage and use this opportunity to gain provider trust.
READ THE ARTICLE

Remote patient monitoring: Will COVID-19 bring about lasting change?

Remote patient monitoring: Will COVID-19 bring about lasting change?


Remote patient monitoring has gained significant traction during the pandemic. Will it last after the crisis? What can manufacturers do to help ensure that patients continue to benefit from these solutions?
READ THE ARTICLE

Rising unemployment and its impact on pharma's top and bottom line

Rising unemployment and its impact on pharma's top and bottom line


How U.S. market access organizations can prepare for changes in market access analytics, contracting and gross-to-net.
READ THE ARTICLE

COVID-19’s long-term impact on US health organizations

COVID-19’s long-term impact on US health organizations


ZS’s Shreesh Tiwari weighs in on how COVID-19 will impact health organizations, and how health plans can navigate uncharted territory.
READ THE ARTICLE

Expediting the return to work: Testing for active virus and antibodies

Expediting the return to work: Testing for active virus and antibodies


Testing for active virus and antibodies is essential, and companies need to be purposeful in how these tests are brought to market, writes ZS’s Ben Hohn. Here’s why.
READ THE ARTICLE

COVID-19 will permanently restructure healthcare

COVID-19 will permanently restructure healthcare


In this article for BioWorld, ZS's Brian Chapman shares his perspective on the short- and long-term changes stemming from COVID-19, and how medtech companies can prepare for recovery.
READ THE ARTICLE ON BIOWORLD.COM

What could be in store for the value and access landscape?

What could be in store for the value and access landscape?


Here's how coronavirus might affect policy changes within the value and access landscape.
READ THE ARTICLE

COVID-19's multifaceted effect on biosimilars

COVID-19's multifaceted effect on biosimilars


In this article published by The Center for Biosimilars, ZS experts review several ways that biosimilars could be affected by COVID-19.
READ THE ARTICLE ON CENTERFORBIOSIMILARS.COM

COVID-19 could prompt higher 2021 insurance premiums, benefit cuts

COVID-19 could prompt higher 2021 insurance premiums, benefit cuts


In this Modern Healthcare article, ZS's Peter Manoogian shares his thoughts on COVID-19's impact on healthcare utilization.
READ THE ARTICLE ON MODERNHEALTHCARE.COM

COVID-19: Now and beyond

COVID-19: Now and beyond


Scientists are working hard to develop a vaccine that protects people from the new coronavirus. ZS’s Ed Schoonveld explains why affordability should be part of the discussion.
READ THE ARTICLE

Is coronavirus the spark that telehealth needs?

Is coronavirus the spark that telehealth needs?


“No matter how long COVID-19 impacts the health of people across the globe, one thing is certain: The increase in patient use of telehealth will only grow,” writes ZS's Victora Summers. Read on for more insights.
READ THE ARTICLE

COVID-19 could significantly alter the contours of US health insurance for years

COVID-19 could significantly alter the contours of US health insurance for years


What do health plans need to know about the ramifications of COVID-19? ZS’s Peter Manoogian discusses the potential implications and what health plans can do amid the outbreak.
READ THE ARTICLE

 
Load More
+ Life sciences commercial strategies

Why women are the future of B-to-B sales

Why women are the future of B-to-B sales


“Future sales success for many companies in the rebounding economy will hinge on attracting and retaining more women for sales roles,” write ZS’s founders. In their latest HBR blog post, they weigh in on why women are the future of B-to-B sales.
READ THE ARTICLE ON HARVARD BUSINESS REVIEW

Podcast: Planning for pharma's new normal

Podcast: Planning for pharma's new normal


ZS’s Pratap Khedkar talks about how pharma companies can align with healthcare’s recent emphasis on telehealth and at-home care, and more pandemic-related trends, in Pharmaceutical Executive’s latest podcast.
LISTEN TO THE PODCAST ON PHARMEXEC.COM

‘Business unusual’: COVID-19 brought commercial changes to pharma and it may stick

‘Business unusual’: COVID-19 brought commercial changes to pharma and it may stick


"Continuing to engage the physicians, understanding what their specific problems are and figuring out if pharma can come up with creative ways to help them, I think, is very much the order of the day," says ZS's Pratap Khedkar in an interview with Scrip.
READ THE ARTICLE IN SCRIP INFORMA PHARMA INTELLIGENCE

Medtechs eye key role of ASCs in return of elective care

Medtechs eye key role of ASCs in return of elective care


ZS's Brian Chapman spoke with Medtech Dive about the evolving role of ambulatory surgery centers.
READ THE ARTICLE ON MEDTECH DIVE

Launching into the new reality: How COVID-19 is reshaping medtech’s launch strategy

Launching into the new reality: How COVID-19 is reshaping medtech’s launch strategy


Many medtech companies are debating whether to launch and how to drive launch excellence post-COVID-19. ZS’s medtech and product launch experts weigh in.
READ THE ARTICLE

Commercial teams: Throw out the rundown

Commercial teams: Throw out the rundown


Breaking out of your comfort zone and learning to run without a script is the first step on the journey to post-COVID success for commercial pharma teams. Here’s how.
READ THE ARTICLE

Using social media analytics to creatively gather insights

Using social media analytics to creatively gather insights


Many pharma companies want to understand the implications of COVID-19. Here’s how social media analytics can help.
READ THE ARTICLE

Repurposing pharma’s field force in a time of ‘business unusual’

Repurposing pharma’s field force in a time of ‘business unusual’


Pharma’s post-pandemic field force will operate in a hybrid role of in-person and virtual engagements. Here’s what manufacturers can do now to prepare.
READ THE ARTICLE

US Unemployment Looms As A Threat To Pharma, But More Impact In 2021

US Unemployment Looms As A Threat To Pharma, But More Impact In 2021


In an interview with Scrip, ZS's Pratap Khedkar addressed how an unemployment-driven increase in Medicaid subscribers could affect pharma.
READ THE ARTICLE IN SCRIP INFORMA PHARMA INTELLIGENCE

Will COVID-19 affect the relationship between mega-payers and pharma companies?

Will COVID-19 affect the relationship between mega-payers and pharma companies?


As so-called “mega-payers” evolve their business models and adjust to a COVID-19 landscape, pharma manufacturers have an opportunity to provide value beyond rebates. Here’s how.
READ THE ARTICLE

Four ways for digital health to win after COVID-19

Four ways for digital health to win after COVID-19


The pandemic has exposed flaws in the U.S. healthcare system. These problems are suited for technology-led innovation, and digital health companies have answered the call. Here’s how the industry can succeed now.
READ THE ARTICLE

Oncology practices look a lot different than they did eight weeks ago

Oncology practices look a lot different than they did eight weeks ago


Oncologists are struggling to find the right balance between fighting cancer and limiting infection risks for their most vulnerable patients. Here are four ways that pharma companies can adjust their engagement strategies accordingly.
READ THE ARTICLE

Road to recovery: What COVID-19 means for medtech in China and around the world

Road to recovery: What COVID-19 means for medtech in China and around the world


As some markets prepare to reopen, what might recovery look like for medtech manufacturers? ZS’s Tim Lee spoke with several medtech executives to find out.
READ THE ARTICLE

Five factors affecting M&A and business development post-COVID-19

Five factors affecting M&A and business development post-COVID-19


In the near term, the rapid spread of the coronavirus has the potential to disrupt deal-making and limit both the ability and willingness of biopharma companies to engage in potential transactions. However, based on prior economic data, the long-term impact is less clear. Here’s what may determine the appetite and ability to execute transactions now.
READ THE ARTICLE

How marketers can drive impact when personal promotion is no longer in person

How marketers can drive impact when personal promotion is no longer in person


With all this disruption happening around us, maybe it’s time to think like a disruptor, write ZS's Jay Lichtenstein and Jeanne Ryan in their latest article for Med Ad News.
READ THE ARTICLE IN MED AD NEWS

Creative sources of customer insight

Creative sources of customer insight


Conducting primary market research is a difficult task these days. Here are six out-of-the-box ways to gather customer insights during COVID-19.
READ THE ARTICLE

Pharma's path to a new 'normal'

Pharma's path to a new 'normal'


Senior pharma leaders are putting patients' needs first as they prepare for the next phase of the pandemic.
VIEW THE INFOGRAPHIC

Interview: How Medtech Companies Are Preparing To Navigate Post-Pandemic Market

Interview: How Medtech Companies Are Preparing To Navigate Post-Pandemic Market


Brian Chapman spoke with Medtech Insight about how the pandemic could permanently change the medtech industry.
READ THE ARTICLE IN MEDTECH INSIGHT

Drugmakers’ financial fortunes during COVID-19 may hinge on their product mix

Drugmakers’ financial fortunes during COVID-19 may hinge on their product mix


In this MedCity News article, ZS's Pratap Khedkar talks about how telemedicine and virtual product launches could help offset some of pharma's challenges.
READ THE ARTICLE ON MEDCITYNEWS.COM

How medtech leaders are revising sales incentive compensation plans

How medtech leaders are revising sales incentive compensation plans


The current environment is taking its toll on sales incentive compensation plans. Here’s how a few medtech leaders are responding.
READ THE ARTICLE

As pharma prepares for a 'new normal,' patient needs come first

As pharma prepares for a 'new normal,' patient needs come first


Biopharma leaders explain why patient needs are a priority as they prepare to move on from the early days of the COVID-19 pandemic.
READ THE ARTICLE

Medtechs adapt to new sales reality amid halt on elective surgeries, hospitals' financial stress

Medtechs adapt to new sales reality amid halt on elective surgeries, hospitals' financial stress


ZS's Brian Chapman tells Medtech Dive what U.S.-based medtech companies can learn from their European counterparts on how to adapt sales teams.
READ THE ARTICLE ON MEDTECHDIVE.COM

Why the COVID-19 crisis is the right time to end dollar-one commission

Why the COVID-19 crisis is the right time to end dollar-one commission


As reps start to crave greater stability in an unstable environment, we're likely to see commission-only plans come to an end. Here's why.
READ THE ARTICLE

Four things sales organizations must do to adapt to the crisis

Four things sales organizations must do to adapt to the crisis


In their latest post for HBR, ZS’s founders weigh in on how to keep your sales organization safe, and what COVID-19 might mean for the future of selling.
READ THE ARTICLE ON HBR.ORG

Four drug distribution and support program considerations for oncology manufacturers

Four drug distribution and support program considerations for oncology manufacturers


Amid the pandemic, healthcare stakeholders are evolving their policies to ensure drug availability and accessibility. Here’s how these changes might affect oncology and specialty pharma manufacturers.
READ THE ARTICLE

Why primary market research is more important than ever

Why primary market research is more important than ever


While in-person market research isn’t a possibility right now, customer insights are more important than ever. Here’s why.
READ THE ARTICLE

Adapting biopharma launches in the COVID-19 landscape

Adapting biopharma launches in the COVID-19 landscape


"With the sudden shift to minimize personal interaction and the refocusing of many hospitals toward COVID-19, cross-functional launch teams must reconsider whether to launch, and if so, how to change their launch execution," write ZS experts Ben Hohn and Judith Kulich in this article published by Pharmaceutical Executive.
READ THE ARTICLE ON PHARMEXEC.COM

How to support rare disease patients during COVID-19

How to support rare disease patients during COVID-19


With so much focus on COVID-19, rare disease patients are left with fear and uncertainty over healthcare systems’ bandwidth to accommodate their needs. Here's how pharma companies can help.
READ THE ARTICLE

Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic

Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic


In this MarketWatch article, ZS's Pratap Khedkar discusses COVID-19's potential impact on current pharma revenue--and the future of the pharma industry.
READ THE ARTICLE ON MARKETWATCH.COM

A sense of purpose: The role of the field force during COVID-19

A sense of purpose: The role of the field force during COVID-19


Managing field teams through this crisis requires leaders to consider the teams' purpose, productivity and energy. Here are five steps to help you get there.
READ THE ARTICLE

Bad for pharma: Sales reps and patients are staying home

Bad for pharma: Sales reps and patients are staying home


In this Scrip article, ZS's Pratap Khedkar discusses COVID-19's impact on sales rep interactions for launch brands and oncology therapies.
READ THE ARTICLE ON PHARMAINTELLIGENCE.INFORMA.COM

Pharma can meet cancer patients’ and oncologists’ unique COVID-19 needs

Pharma can meet cancer patients’ and oncologists’ unique COVID-19 needs


Cancer patients and oncologists are facing new obstacles. Oncology manufacturers can help.
READ THE ARTICLE

COVID-19 and pharma's in-person sales model

COVID-19 and pharma's in-person sales model


All industries are being disrupted by the COVID-19 outbreak, and pharma is no exception. ZS’s Pratap Khedkar explains what it means for sales reps.
READ THE ARTICLE

"Time to flip the digital switch": COVID-19 and pharma sales

"Time to flip the digital switch": COVID-19 and pharma sales


Pharmaceutical Executive shares insights from ZS's Pratap Khedkar and Daniel Brox on six approaches that pharma companies can take to help their sales reps be effective from home.
READ THE ARTICLE ON PHARMEXEC.COM

Pharma salesforces brought to a halt as coronavirus shutters economy

Pharma salesforces brought to a halt as coronavirus shutters economy


In this BioPharma Dive article, ZS's Pratap Khedkar joins industry experts who discuss how pharma companies are managing their sales forces during the COVID-19 outbreak.
READ THE ARTICLE ON BIOPHARMADIVE.COM

 
Load More
+ R&D and medical

Social distancing shines a light on virtual reality for clinical trials

Social distancing shines a light on virtual reality for clinical trials


As people seek to avoid unnecessary interactions, healthcare services are shifting to online formats like telemedicine and online healthcare reimbursement. Here are opportunities to further explore this technology.
READ THE ARTICLE

How can medical and clinical teams prepare for an uncertain post-pandemic future?

How can medical and clinical teams prepare for an uncertain post-pandemic future?


How can medical affairs prepare for an uncertain future? Consider scenario planning.
READ THE ARTICLE

COVID-19 vaccines: Who might win the race to the global market?

COVID-19 vaccines: Who might win the race to the global market?


ZS experts weigh in on the four key factors that might influence the success and global access of COVID-19 vaccine candidates.
READ THE ARTICLE

What if medical affairs engaged its audiences like Netflix?

What if medical affairs engaged its audiences like Netflix?


COVID-19 may permanently change how medical affairs communicates with customers, increasing the importance of digital engagement. How can you prepare for this new, digital-first world? Follow Netflix’s lead.
READ THE ARTICLE

Addressing COVID-19 challenges: Quick wins for medical affairs leaders

Addressing COVID-19 challenges: Quick wins for medical affairs leaders


COVID-19 is shifting priorities across healthcare, leading to changes in how physicians’ want to access scientific information. Here’s how medical affairs teams can understand HCPs’ current challenges and better meet their needs.
READ THE ARTICLE

Are we seeing a plateau in new entrants to the COVID-19 clinical pipeline?

Are we seeing a plateau in new entrants to the COVID-19 clinical pipeline?


While many clinical trials are taking place, the number of new entrants in the race to address COVID-19 may be slowing down, according to ZS experts.
READ THE ARTICLE

If COVID-19 clinical trial numbers are increasing, why are some studies closing?

If COVID-19 clinical trial numbers are increasing, why are some studies closing?


Why are some COVID-19 clinical trials being stopped? ZS experts weigh in.
READ THE ARTICLE

Will you be ready to reopen clinical trials?

Will you be ready to reopen clinical trials?


When the world moves forward again, countless clinical trials that had been put on hold will resume at the same time. Will you be ready with your reinitiation strategy?
READ THE ARTICLE

The COVID-19 pipeline: Introducing our weekly report and vaccine and treatment pipeline tracker

The COVID-19 pipeline: Introducing our weekly report and vaccine and treatment pipeline tracker


ZS experts share the latest on the COVID-19 clinical development landscape.
READ THE ARTICLE

COVID-19 Vaccine and Treatment Pipeline Weekly Tracker

COVID-19 Vaccine and Treatment Pipeline Weekly Tracker


We are tracking the rising number of clinical trials and sharing updates on key study results and development milestones on a weekly basis. View the infographic to see the latest updates.
VIEW THE INFOGRAPHIC

COVID-19 could permanently change how scientific data is shared

COVID-19 could permanently change how scientific data is shared


Virtual conferences, podcasts and alternative peer review strategies are accelerating access to scientific data. Here's why these methods could endure beyond the pandemic.
READ THE ARTICLE

How should biopharma companies prioritize their pipeline programs during COVID-19?

How should biopharma companies prioritize their pipeline programs during COVID-19?


Drug development pipelines are being re-prioritized. “There may be opportunity to redesign clinical programs to face less impact from COVID-19.”
READ THE ARTICLE

The COVID-19 pipeline: An unprecedented global clinical development effort

The COVID-19 pipeline: An unprecedented global clinical development effort


ZS experts share the latest news on the COVID-19 clinical development landscape.
READ THE ARTICLE

Four key actions clinical ops can take now to avoid disruptions

Four key actions clinical ops can take now to avoid disruptions


"In accordance with recommendations from the FDA, there are four key actions that biopharmaceutical sponsors can take immediately to offset disruptions," write four ZS experts in this article published by Applied Clinical Trials.
READ THE ARTICLE ON APPLIEDCLINICALTRIALSONLINE.COM

How medical affairs teams need to adapt to COVID-19

How medical affairs teams need to adapt to COVID-19


In this article on PharmExec.com, ZS's Sarah Jarvis discusses the role of medical affairs teams in the response to COVID-19.
READ THE ARTICLE ON PHARMEXEC.COM

Clinical development risks and issues in a COVID-19 world

Clinical development risks and issues in a COVID-19 world


"Concerns about whether to begin trials are significant but perhaps pale in comparison to what to do about ongoing studies." ZS's Jonathan Rowe discusses clinical trial risk management.
READ THE ARTICLE

COVID-19 clinical development: What's in the pipeline to address the SARS-CoV-2 pandemic?

COVID-19 clinical development: What's in the pipeline to address the SARS-CoV-2 pandemic?


ZS experts offer a detailed look at the current clinical development landscape to address COVID-19.
READ THE ARTICLE

 
Load More
+ Marketplace impact

How COVID-19 will shake up the commercial landscape for U.S. airlines

How COVID-19 will shake up the commercial landscape for U.S. airlines


Here's how the commercial environment for U.S. airlines will change, what customers will expect from them and how airlines can stay competitive.
READ THE ARTICLE

Is B-to-B demand rebounding?

Is B-to-B demand rebounding?


As some states begin to reopen, the question on everyone’s mind is: When will business pick back up? To find out, ZS surveyed insurance companies to track how demand is being impacted in the current environment. Here are our updated results.
READ THE ARTICLE

What companies can learn from my son's school's response to COVID-19

What companies can learn from my son's school's response to COVID-19


When it comes to dealing with the pandemic, companies have a lot in common with schools. Here are some lessons.
READ THE ARTICLE

How COVID-19 is impacting B-to-B sales demand in the U.S.

How COVID-19 is impacting B-to-B sales demand in the U.S.


ZS surveyed insurers to get an industry-wide perspective on how sales are being affected by this crisis. Here are some early trends.
READ THE ARTICLE

As tourism rebounds, revenue management and sales must collaborate better

As tourism rebounds, revenue management and sales must collaborate better


Improved collaboration between revenue management and sales teams means more growth through the recovery period and beyond. Here’s how to achieve it.
READ THE ARTICLE

How sales leaders are using KPIs to navigate coronavirus uncertainty

How sales leaders are using KPIs to navigate coronavirus uncertainty


In times of uncertainty, maximizing the efficiency of your existing data and adjusting KPIs to take the pulse of your customer can help you plan your next moves.
READ THE ARTICLE

Adjusting revenue management strategies during the travel industry's recovery

Adjusting revenue management strategies during the travel industry's recovery


When the travel industry hits recovery mode, revenue management teams must increase their agility and adapt to new forecasting methods. Here’s how.
READ THE ARTICLE

How coronavirus will reshape U.S. airlines: Network implications

How coronavirus will reshape U.S. airlines: Network implications


Why the decisions airlines make over the next year will lay the foundation of the domestic network for the next decade.
READ THE ARTICLE

Adapting and thriving as a middle-market business in today's shifting landscape

Adapting and thriving as a middle-market business in today's shifting landscape


ZS co-hosted a virtual roundtable for a private equity fund comprised of the commercial leaders at middle-market companies across B-to-B sectors and life sciences. Here are the early actions that these leaders are taking to address the economic and social impact of COVID-19, and how they’re finding new opportunities along the way.
READ THE ARTICLE

How to pay and support your sales force in the wake of COVID-19

How to pay and support your sales force in the wake of COVID-19


Here are five immediate steps to address reps' compensation concerns.
READ THE ARTICLE

How coronavirus is impacting meetings and how sales teams can adapt

How coronavirus is impacting meetings and how sales teams can adapt


Fewer touch points with teams, partners and customers makes a customer-centric marketing strategy even more important. ZS’s Steve Marley offers advice for executing it.
READ THE ARTICLE

Coronavirus response: Four ways to adjust your sales compensation plan

Coronavirus response: Four ways to adjust your sales compensation plan


ZS’s Chad Albrecht explains how to adjust your sales compensation plan.
READ THE ARTICLE

Keep or cancel your incentive trips?

Keep or cancel your incentive trips?


As the coronavirus spreads, sales organizations are debating what to do with their annual sales incentive trips. Here are three options to consider.
READ THE ARTICLE

How sales leaders are tackling coronavirus fallout

How sales leaders are tackling coronavirus fallout


The best way to guide your sales teams now is with strong, calm leadership and a thoughtful plan of action. ZS’s Jason Brown and Emily Alexander spoke with sales leaders about their plans.
READ THE ARTICLE

 
Load More

Channeling our core purpose

Supporting our employees

Our first priority is to keep our employees safe and healthy, so we’ve taken steps including halting all travel and in-person meetings, and instituting a 100% work-from-home model in all of our offices. We’ve also invited employees to use our web conferencing platform to stay connected with friends and family, ramped up our HR efforts to ensure that employees are aware of their access to telehealth and mental health resources, and temporarily expanded our family leave program to ensure that employees can take the time they need to care for their families and themselves.

Supporting our communities

We believe in contributing our skills and resources to make a positive difference in the communities where we live and work. Given our deep roots in healthcare and our extensive data and analytics expertise, we’re contributing our knowledge and skills to help combat the novel coronavirus pandemic through several initiatives. For example, we’re working with an organization on a pro bono basis to build a “hub” to match volunteer staffing needs with individuals who’d like to volunteer through a central portal.
Learn more about our corporate social responsibility efforts via our ZS Cares program.

Supporting our employees Supporting our communities
Our first priority is to keep our employees safe and healthy, so we’ve taken steps including halting all travel and in-person meetings, and instituting a 100% work-from-home model in all of our offices. We’ve also invited employees to use our web conferencing platform to stay connected with friends and family, ramped up our HR efforts to ensure that employees are aware of their access to telehealth and mental health resources, and temporarily expanded our family leave program to ensure that employees can take the time they need to care for their families and themselves. We believe in contributing our skills and resources to make a positive difference in the communities where we live and work. Given our deep roots in healthcare and our extensive data and analytics expertise, we’re contributing our knowledge and skills to help combat the novel coronavirus pandemic through several initiatives. For example, we’re working with an organization on a pro bono basis to build a “hub” to match volunteer staffing needs with individuals who’d like to volunteer through a central portal.
  Learn more about our corporate social responsibility efforts via our ZS Cares program.

“While the world comes together to combat this health challenge, I’m so proud of the ways in which our firm—and individuals within it—are rising to the occasion. ZSers are stepping up and thinking creatively about how to help our clients, help each other and help the world.”

– Chris Wright, CEO, ZS

How can we help?

Load More Blogs